Pharmacodynamics of human immunodeficiency virus type 1 protease inhibitors

Clinical Infectious Diseases

Volumn 30, Issue SUPPL. 2, 2000, Pages

  Acosta, E P ^a   Kakuda, T N ^a   Brundage, R C ^a   Anderson, P L ^a   Fletcher, C V ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPRENAVIR; INDINAVIR; NELFINAVIR; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR;

AREA UNDER THE CURVE; CONFERENCE PAPER; DRUG ACTIVITY; DRUG MONITORING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IC 50; MAJOR CLINICAL STUDY; PRIORITY JOURNAL;

CLINICAL TRIALS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS;

EID: 0034458321     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/313852     Document Type: Conference Paper

References (37)

1. Concentration-controlled zidovudine therapy
2. Intracellular phosphorylation of stavudine and 3TC correlates with their antiviral activity in naive and zidovudine experienced HIV-infected patients
3. Intracellular phosphorylation of zidovudine (ZDV) and other nucleoside reverse transcriptase inhibitors (RTI) used for human immunodeficiency virus (HIV) infection
4. A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease
5. A preliminary evaluation of nelfinavir mesylate, an inhibitor of human immunodeficiency virus (HIV)-1 protease, to treat HIV infection
6. Fortovase (SQV) soft gel capsule BID regimens in combination with 2 nucleosides or nelfinavir plus 1 nucleoside in HIV-infected patients
7. Activities of the human immunodeficiency virus type 1 (HIV-1) protease inhibitor nelfinavir mesylate in combination with reverse transcriptase and protease inhibitors against acute HIV-1 infection in vitro
8. Patterns of cross-resistance among protease inhibitors in 483 clinical HIV-1 isolates
9. Activity of a ritonavir plus saquinavir-containing regimen in patients with virologic evidence of indinavir or ritonavir failure
10. 1-acid glycoprotein concentration in normal volunteers
11. 1-acid glycoprotein levels in AIDS patients before and after short-term treatment with zidovudine
12. 1-acid glycoprotein on the anti-human immunodeficiency virus (HIV) activity of the protease inhibitor CGP 61755: A comparative study with other relevant HIV protease inhibitors
13. - T-cell counts in HIV-infected patients
14. Plasma concentrations of saquinavir determine HIV-1 RNA response over a 48-week period
15. Combination therapy with saquinavir soft gelatin capsules plus nucleoside antiretroviral agents in HIV-infected children
16. Exposure-response relationships for saquinavir, zidovudine, and zalcitabine in combination therapy
17. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir
18. Multiple-dose pharmacokinetics of ritonavir in human immunodeficiency virus-infected subjects
19. Pharmacodynamic relationship between ritonavir side effects and its plasma concentrations
20. Therapeutic drug monitoring in HIV-infected patients receiving indinavir
21. Relationships between indinavir pharmacokinetics and antiviral activity in phase I/II trials
22. Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor
23. A 24-week open-label phase I/II evaluation of the HIV protease inhibitor MK-639 (indinavir)
24. A pilot study of nevirapine, indinavir, and lamivudine among patients with advanced human immunodeficiency virus disease who have had failure of combination nucleoside therapy
25. Antiviral effect and pharmacokinetic interaction between nevirapine and indinavir in persons infected with human immunodeficiency virus type 1
26. Indinavir concentrations and antiviral effect
27. Low plasma concentrations of indinavir are related to virological treatment failure in HIV-1-infected patients on indinavir-containing triple therapy
28. Urological complaints in relation to indinavir plasma concentrations in HIV-infected patients
29. Virologic response-plasma drug concentration relationship in phase III study of nelfinavir mesylate (VIRACEPT)
30. Pharmacodynamics of 141W94 as determined by short term change in HIV RNA: Influence of viral isolate baseline EC50
31. Toxicity, efficacy, plasma drug concentrations and protease mutations in patients with advanced HIV infection treated with ritonavir and saquinavir. Swiss Cohort Study
32. The effect of plasma drug concentrations on HIV-1 clearance rate during quadruple drug therapy
33. Therapeutic drug monitoring
34. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection